小剂量利妥昔单抗联合短期口服泼尼松治疗自身免疫性溶血性贫血的疗效

陆欣; 王海军; 赵丽云; 李玉伟; 王助衡

doi:10.13201/j.issn.1004-2806.2015.03.014

小剂量利妥昔单抗联合短期口服泼尼松治疗自身免疫性溶血性贫血的疗效

- 1. 河北医科大学附属邢台市人民医院血液科(河北邢台, 054031);
- 2. 北京市大兴区人民医院重症医学科

详细信息

通讯作者: 王助衡,E-mail:1147070617@qq.com

中图分类号: R556.6

收稿日期: 2014-05-28

Efficacy of low-dose rituximab combined with short-term oral prednisone in the treatment of idiopathic autoimmune hemolytic anemia

- 1. Department of Hematology, Xingtai People's Hospital Affiliated Hebei Medical University, Xingtai, 054031, China;
- 2. Intensive Care Unit, People's Hospital of Beijing Daxing District

More Information

Corresponding author: WANG Zhuheng, E-mail: 1147070617@qq.com

Received Date: 28 May 2014

摘要

摘要: 目的:评价小剂量利妥昔单抗联合短期口服泼尼松治疗自身免疫性溶血性贫血(AIHA)的临床疗效。方法:32例确诊的AIHA患者接受小剂量利妥昔单抗(静脉滴注100 mg,每周1次,连用4周)联合短期口服泼尼松治疗。分别于治疗后第6、12、24和36个月进行随访,并收集患者临床转归、血常规和溶血性指标等资料。结果:治疗后第6、12、24和36个月,患者的血液学指标均较治疗前明显改善,总缓解率分别为90%、100%、100%和89%,无复发生存率分别为87%、79%、68%和68%。其中温抗体自身免疫性溶血性贫血(WAIHA)患者的总缓解率稍高于冷凝集患者,冷凝集患者的复发风险较WAIHA患者高(HR 2.1,95%CI 0.6~7.9)。治疗后各时间点红细胞抗体(抗球蛋白试验)均有下降。结论:使用小剂量利妥昔单抗联合短期口服泼尼松治疗AIHA有效,可以使患者缓解,并能够减少自身抗体的产生。
- 贫血,溶血性,自身免疫性 /
- 利妥昔单抗 /
- 冷凝集素病 /
- 温抗体 /
- 抗体治疗
Abstract: Objective:To evaluate the sustained response to low-dose rituximab combined with short-term oral prednisone in the treatment of autoimmune hemolytic anemia (AIHA).Method:A total of 32 patients diagnosed AIHA were treated with low-dose rituximab (100 mg fixed dose and 4 weekly infusions) along with a short course of oral prednisone.The clinical examination,blood counts and hemolytic markers were collected at 6,12,24 and 36 months.Result:A satisfactory response was achieved at all time points compared to enrollment.The overall response was 90%,100%,100% and 89%,and the relapse-free survival rate was 87%,79%,68% and 68% at 6,12,24,and 36 months,respectively.Response rate was slightly higher in warm-antibody reactive autoimmune haemolytic anaemia (WAIHA) than that in hemagglutinin disease (CHD),and relapse risk was higher in CHD than that in WAIHA (HR 2.1,95%CI 0.6 to 7.9).Anti-RBC antibody production by mitogen-stimulated direct antiglobulin test significantly decreased at all time points.Conclusion:Low-dose rituximab combined with short-term oral prednisone treatment is effective and induces sustained responses in AIHA,and it can down-regulate the autoantibody production.
- autoimmune hemolytic anemia /
- rituximab /
- cold hemagglutinin disease /
- warm-antibody /
- antibody therapeutics

HTML全文

参考文献(6)

[1]	张之南,沈悌.血液病诊断及疗效标准[M].北京:科学出版社,2008:69-70.
[2]	Swiecicki PL,Hegerova LT,Gertz MA.Cold agglutinin disease[J].Blood,2013,122:1114-1121.
[3]	Crowther M,Chan YL,Garbett IK,et al.Evidence-based focused review of the treatment of idiopathic warm immune haemolytic anaemia in adults[J].Blood,2011,118:4036-4040.
[4]	Lechner K,Jäger U.How I treat autoimmune hemolytic anemias in adults[J].Blood,2010,116:1831-1838.
[5]	Patel VL,Mahévas M,Lee SY,et al.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood,2012,119:5989-5995.
[6]	Penalver FJ,Alvarez-Larrán A,Díez-Martin JL,et al.Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia[J].Ann Hematol,2010,89:1073-1080.